K2M GROUP HOLDINGS, INC. (NASDAQ:KTWO) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.

The Annual Meeting of Shareholders (the “Annual Meeting”) of K2M Group Holdings, Inc. (the “Company”) was held on June 5, 2018. The final voting results on each of the matters submitted to a vote of the Company’s shareholders at the Annual Meeting are set forth below:

(1) A proposal to elect three Class I directors to the Company’s Board of Directors for terms ending in 2021. The shareholders elected each of the nominees to the Board of Directors with the following votes:

(2) A proposal to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2018. The proposal was approved and received the following votes:

(3) A proposal to determine, by a non-binding shareholder advisory vote, whether a non-binding shareholder advisory vote to approve the compensation paid to the Company’s named executive officers should occur every one, two or three years.

Based on the results of the vote, and consistent with the Board of Directors’ recommendation, the Board of Directors of the Company has determined that future non-binding votes of shareholders to approve the compensation of the named executive officers will be submitted annually to the Company’s shareholders until the next non-binding shareholder vote on the frequency of shareholder votes on executive compensation, or until the Board of Directors otherwise determines a different frequency for such non-binding votes.

(4) A proposal to approve, in a non-binding advisory vote, the compensation paid to the Company’s named executive officers.

About K2M GROUP HOLDINGS, INC. (NASDAQ:KTWO)

K2M Group Holdings, Inc. is a medical device company focused on designing, developing and commercializing spine technologies and techniques. The Company’s spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor. The Company is engaged in designing, development and commercialization of products for patients suffering from degenerative spinal conditions. Its products consist of implants, disposables and instruments, which are marketed and sold primarily to hospitals for use by spine surgeons. The Company’s product portfolio contains over 70 product lines that are used in spine surgeries, minimally invasive spine (MIS) and degenerative surgeries. It markets or sells its products in the United States and over 36 other countries. The Company’s technologies include MESA, Rail 4D, Quicket Deformity, CAPRI, SERENGETI, RAVINE, EVEREST, CASCADIA and tifix.